Literature DB >> 16876015

Grandpa and I have dystrophinopathy?: approach to asymptomatic hyperCKemia.

Montri Saengpattrachai1, Peter N Ray, Cynthia E Hawkins, Alan Berzen, Brenda L Banwell.   

Abstract

This report describes three males from a single kinship, ages 7, 8, and 67 years with clinically asymptomatic dystrophinopathy. The index case was an 8-year-old male evaluated for asymptomatic but persistently elevated serum creatine kinase levels. Muscle biopsy demonstrated a mild myopathy, without necrotic fibers. Immunostaining for dystrophin revealed a slight reduction in sarcolemmal reactivity for the amino terminus of dystrophin. Dystrophin gene analysis revealed a deletion of exon 45 to exon 51. Genetic analysis identified two other affected males (age 7 years and 67 years), as well as four female carriers in the same family. The 7-year-old male had mildly increased creatine kinase levels with normal muscle strength. The 67-year-old grandfather had normal neuromuscular examination and serum creatine kinase levels. Asymptomatic dystrophinopathy in late adulthood is exceptionally rare, and highlights the importance of consideration of dystrophin mutation analysis in patients with hyperCKemia, even in the absence of muscle weakness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876015     DOI: 10.1016/j.pediatrneurol.2006.01.004

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  9 in total

Review 1.  The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.

Authors:  Qi-Long Lu; Toshifumi Yokota; Shin'ichi Takeda; Luis Garcia; Francesco Muntoni; Terence Partridge
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

2.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.

Authors:  Karen Anthony; Sebahattin Cirak; Silvia Torelli; Giorgio Tasca; Lucy Feng; Virginia Arechavala-Gomeza; Annarita Armaroli; Michela Guglieri; Chiara S Straathof; Jan J Verschuuren; Annemieke Aartsma-Rus; Paula Helderman-van den Enden; Katherine Bushby; Volker Straub; Caroline Sewry; Alessandra Ferlini; Enzo Ricci; Jennifer E Morgan; Francesco Muntoni
Journal:  Brain       Date:  2011-11-18       Impact factor: 13.501

3.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Authors:  Sebahattin Cirak; Virginia Arechavala-Gomeza; Michela Guglieri; Lucy Feng; Silvia Torelli; Karen Anthony; Stephen Abbs; Maria Elena Garralda; John Bourke; Dominic J Wells; George Dickson; Matthew J A Wood; Steve D Wilton; Volker Straub; Ryszard Kole; Stephen B Shrewsbury; Caroline Sewry; Jennifer E Morgan; Kate Bushby; Francesco Muntoni
Journal:  Lancet       Date:  2011-07-23       Impact factor: 79.321

4.  DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy.

Authors:  Kevin M Flanigan; Diane M Dunn; Andrew von Niederhausern; Michael T Howard; Jerry Mendell; Anne Connolly; Carol Saunders; Ann Modrcin; Majed Dasouki; Giacomo P Comi; Roberto Del Bo; Angela Pickart; Richard Jacobson; Richard Finkel; Livija Medne; Robert B Weiss
Journal:  Neuromuscul Disord       Date:  2009-09-29       Impact factor: 4.296

Review 5.  Targeting RNA to treat neuromuscular disease.

Authors:  Francesco Muntoni; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

6.  Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype.

Authors:  Nanna Witting; Morten Duno; John Vissing
Journal:  Acta Myol       Date:  2011-12

7.  A rare subclinical or mild type of Becker muscular dystrophy caused by a single exon 48 deletion of the dystrophin gene.

Authors:  Janusz G Zimowski; Jacek Pilch; Magdalena Pawelec; Joanna K Purzycka; Jolanta Kubalska; Karolina Ziora-Jakutowicz; Magdalena Dudzińska; Jacek Zaremba
Journal:  J Appl Genet       Date:  2017-02-28       Impact factor: 3.240

8.  Ethnicity-related DMD Genotype Landscapes in European and Non-European Countries.

Authors:  Rita Selvatici; Rachele Rossi; Fernanda Fortunato; Cecilia Trabanelli; Yamina Sifi; Alice Margutti; Marcella Neri; Francesca Gualandi; Lena Szabò; Balint Fekete; Lyudmilla Angelova; Ivan Litvinenko; Ivan Ivanov; Yurtsever Vildan; Oana Alexandra Iuhas; Mihaela Vintan; Carmen Burloiu; Butnariu Lacramioara; Gabriela Visa; Diana Epure; Cristina Rusu; Daniela Vasile; Magdalena Sandu; Dmitry Vlodavets; Monica Mager; Theodore Kyriakides; Sanja Delin; Ivan Lehman; Jadranka Sekelj Fureš; Veneta Bojinova; Mariela Militaru; Velina Guergueltcheva; Birute Burnyte; Maria Judith Molnar; Niculina Butoianu; Selma Dounia Bensemmane; Samira Makri-Mokrane; Agnes Herczegfalvi; Monica Panzaru; Adela Chirita Emandi; Anna Lusakowska; Anna Potulska-Chromik; Anna Kostera-Pruszczyk; Andriy Shatillo; Djawed Bouchenak Khelladi; Oussama Dendane; Mingyan Fang; Zhiyuan Lu; Alessandra Ferlini
Journal:  Neurol Genet       Date:  2020-12-24

9.  EMQN best practice guidelines for genetic testing in dystrophinopathies.

Authors:  Carl Fratter; Raymond Dalgleish; Stephanie K Allen; Rosário Santos; Stephen Abbs; Sylvie Tuffery-Giraud; Alessandra Ferlini
Journal:  Eur J Hum Genet       Date:  2020-05-18       Impact factor: 4.246

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.